Comparison of 18F-fluoro-L-DOPA, 18F-fluoro- deoxyglucose, and18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 12, 2009, Pages 4757-4767

  Timmers, Henri J L M ^a,c   Chen, Clara C ^b   Carrasquillo, Jorge A ^b,d   Whatley, Millie ^b   Ling, Alexander ^b   Havekes, Bastiaan ^a,e   Eisenhofer, Graeme ^f   Martiniova, Lucia ^a   Adams, Karen T ^a   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; CARBIDOPA; FLUORODEOXYGLUCOSE F 18; FLUORODOPAMINE F 18; RADIOPHARMACEUTICAL AGENT; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE SUBUNIT B; SUCCINATE DEHYDROGENASE SUBUNIT D; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; (3 IODOBENZYL)GUANIDINE; 6 FLUORODOPAMINE; 6-FLUORODOPAMINE; DIAGNOSTIC AGENT; DOPA; DOPAMINE; DRUG DERIVATIVE;

ADRENAL GLAND; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SCINTISCANNING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADOLESCENT; ADRENAL TUMOR; AGED; GENETICS; MIDDLE AGED; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; FLUORODEOXYGLUCOSE F18; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 73249127006     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1248     Document Type: Article

References (42)

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C 2004 Pathology and genetics: World Health Organization classification of tumours of endocrine organs. Oxford, UK: Oxford University Press
2. Lenders JW, Eisenhofer G, Mannelli M, Pacak K 2005 Phaeochromocytoma. Lancet 366:665-675
3. Pacak P, Keiser H, Eisenhofer G 2005 Pheochromocytoma. In: De Groot LJ, Jameson JL, eds. Textbook of endocrinology. Philadelphia: Elsevier Saunders, Inc.; 2501-2534
4. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G 2002 Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287:1427-1434
5. Ilias I, Shulkin B, Pacak K 2005 New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol Metab 16:66-72
6. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC 1999 Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212:35-41
7. Taniguchi K, Ishizu K, Torizuka T, Hasegawa S, Okawada T, Ozawa T, Iino K, Taniguchi M, Ikematsu Y, Nishiwaki Y, Kida H, Waki S, Uchimura M 2001 Metastases of predominantly dopamine-secreting phaeochromocytoma that did not accumulate meta-iodobenzylguanidine: imaging with whole body positron emission tomography using 18F-labelled deoxyglucose. Eur J Surg 167:866-870
8. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JW, Pacak K 2007 Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25:2262-2269
9. Bhatia KS, Ismail MM, Sahdev A , Rockall AG, Hogarth K, Canizales A, Avril N, Monson JP, Grossman AB, Reznek RH 2008 (123)I- metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 69:181-188
10. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP 2002 Pheochromocytomas: detection with 18FDOPAwhole body PET-initial results. Radiology 222:507-512
11. Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E, Neumann HP 2003 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30:689-694
12. Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R, Eisenhofer G 2001 A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab 86:3641-3646
13. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS 2001 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38:6-8
14. van der Harst E, de HerderWW,Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ 2001 [(123)I]-metaiodobenzylguanidine and [(111)In]-octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685-693
15. Van Der Horst-Schrivers AN, Jager PL, Boezen HM, Schouten JP, Kema IP, Links TP 2006 Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas-experience and metaanalysis. Anticancer Res 26:1599-1604
16. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S,RohmerV, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP 2005 Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23:8812-8818
17. Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, Pinto PA, LaiE W, Pacak K). et al 2007 The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol 156:483-487
18. Linnoila RI, Keiser HR, Steinberg SM, Lack EE 1990 Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21:1168-1180
19. Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, Ling A, Eisenhofer G, Adams KT, Pacak K 2007 The effects of carbidopa on uptake of 6-18F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 48:1599-1606
20. Eisenhofer G 2001 The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91:35-62
21. Pearse AG 1969 The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 17:303-313
22. Belhocine T, Spaepen K, Dusart M, Castaigne C, Muylle K, Bourgeois P, Bourgeois D, Dierickx L, Flamen P 2006 18FDG PET in oncology: the best and the worst. Int J Oncol 28:1249-1261 (Review)
23. Pauwels EK, Sturm EJ, Bombardieri E, Cleton FJ, Stokkel MP 2000 Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 126:549-559
24. Lynn MD, Shapiro B, Sisson JC, Beierwaltes WH, Meyers LJ, Ackerman R, Mangner TJ 1985 Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology 155:789-792
25. Becherer A, Szabo M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R, Kletter K 2004 Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 45:1161-1167
26. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, Moser E, Nitzsche E 2001 Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 220:373-380
27. Nanni C, Rubello D, Fanti S 2006 18F-DOPA PET/CT and neuroendocrine tumours. Eur J Nucl Med Mol Imaging 33:509-513
28. Brink I, Schaefer O, Walz M, Neumann HP 2006 Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clin Nucl Med 31:39-41
29. Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW 2009 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med 50:513-519
30. Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE, Sluiter WJ, de Vries EG, Links TP 2009 18F-DOPA PET is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, CT, and MRI in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 94:3922-3930
31. Taieb D, Tessonnier L, Sebag F , Niccoli-Sire P, Morange I, Colavolpe C, De Micco C, Barlier A, Palazzo FF, Henry JF, Mundler O 2008 The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf) 69:580-586
32. Mackenzie IS, Gurnell M, Balan KK, Simpson H, Chatterjee K, Brown MJ 2007 The use of 18-fluoro-dihydroxyphenylalanine and 18- fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol 157:533-537
33. Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M, McElroy B, Pacak K 2003 Superiority of 6-[18F]fluorodopamine positron emission tomography versus [131I]metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88:4083-4087
34. Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE, Krohn KA, Mankoff DA 2006 [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol 13:187-197
35. Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Mannelli M, Goldstein DS, Linehan WM, Lenders JW, Pacak K 2001 Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86:1999-2008
36. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D, Lenders JW, Pacak K 2007 Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92:779-786
37. Huynh TT, Pacak K, Brouwers FM, Abu-Asab MS, Worrell RA, Walther MM, Elkahloun AG, Goldstein DS, Cleary S, Eisenhofer G 2005Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur J Endocrinol 153:551-563
38. Taieb D, Sebag F, Barlier A, Tessonnier L, Palazzo FF, Morange I, Niccoli-Sire P, Fakhry N, De Micco C, Cammilleri S, Enjalbert A, Henry JF, Mundler O 2009 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med 50:711-717
39. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Kerlan V, Plouin PF, Rötig A, Jeunemaitre X 2002 Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 87:4771-4774
40. Warburg O 1956Onthe origin of cancer cells. Science 123:309-314
41. Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazúrová I, Adams KT, Perera S, Pacak K 2008 Comparison of 6-18F-fluorodopaminePETwith 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 49:1613-1619
42. Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, Grassetto G, Rubello D, Nanni C, Franchi R 2008 Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother 62:667-671